GAF Healthcare
Обзор направления

Лучшие больницы для «Pancreas Transplant» в Индия

90 больниц по направлению «Трансплантация печени и гепатобилиарная хирургия» представлены в нашей сети в Индия, с аккредитацией JCI, NABH, ISO, NABL.

90
больниц в списке
5
городов
4.5
средний рейтинг
5
вида аккредитации
Короткий ответ

На этой странице перечислены больницы направления «Трансплантация печени и гепатобилиарная хирургия» (включая Pancreas Transplant) в Индия, включая Nanavati Super Specialty Hospital, Apollo Hospitals, Medanta - The Medicity, Artemis Hospital и другие.

По нашим опубликованным данным, стоимость варьируется от 28,000 до 55,000 долларов США в зависимости от диагноза.

Спросите нас о «Pancreas Transplant» в Индия

Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.

Сравните 90 аккредитованных больниц (Трансплантация печени и гепатобилиарная хирургия) в Индия

🇮🇳 Nanavati Super Specialty Hospital

Mumbai, India 5 (12 отзывов) 350 коек

Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 5 из 5 (12 отзывов)Аккредитация: JCI, NABH350 коек
Специализации и аккредитация
OncologyCardiac SurgeryNeurosciencesTransplantBariatrics
Аккредитация JCI, NABH
5/5
Рейтинг
1950
Основана в
350
Койки
Mumbai, India
Расположение
#2
Apollo Hospitals

🇮🇳 Apollo Hospitals

New Delhi, India 4.9 (1240 отзывов) 1,000 коек

Больница занимает 2-е место в этом списке по указанному рейтингу (4.9/5, 1240 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.9 из 5 (1240 отзывов)Аккредитация: JCI, NABH1,000 коек
Специализации и аккредитация
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Аккредитация JCI, NABH
4.9/5
Рейтинг
1983
Основана в
1,000
Койки
New Delhi, India
Расположение
#3
Medanta - The Medicity

🇮🇳 Medanta - The Medicity

Gurgaon, India 4.9 (2150 отзывов) 1,600 коек

Больница занимает 3-е место в этом списке по указанному рейтингу (4.9/5, 2150 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.9 из 5 (2150 отзывов)Аккредитация: JCI, NABH1,600 коек
Специализации и аккредитация
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Аккредитация JCI, NABH
4.9/5
Рейтинг
2009
Основана в
1,600
Койки
Gurgaon, India
Расположение
#4
Artemis Hospital

🇮🇳 Artemis Hospital

Gurgaon, India 4.9 (64 отзывов) 750 коек

Больница занимает 4-е место в этом списке по указанному рейтингу (4.9/5, 64 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.9 из 5 (64 отзывов)Аккредитация: JCI, NABH750 коек
Специализации и аккредитация
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Аккредитация JCI, NABH
4.9/5
Рейтинг
2007
Основана в
750
Койки
Gurgaon, India
Расположение
#5
Fortis Memorial Research Institute

🇮🇳 Fortis Memorial Research Institute

Gurgaon, India 4.8 (1100 отзывов) 1,000 коек

Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 1100 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.8 из 5 (1100 отзывов)Аккредитация: JCI, NABH1,000 коек
Специализации и аккредитация
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
Аккредитация JCI, NABH
4.8/5
Рейтинг
1996
Основана в
1,000
Койки
Gurgaon, India
Расположение
#6
Kokilaben Dhirubhai Ambani Hospital

🇮🇳 Kokilaben Dhirubhai Ambani Hospital

Mumbai, India 4.8 (1800 отзывов) 750 коек

Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.8 из 5 (1800 отзывов)Аккредитация: JCI, NABH750 коек
Специализации и аккредитация
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
Аккредитация JCI, NABH
4.8/5
Рейтинг
2009
Основана в
750
Койки
Mumbai, India
Расположение
#7
Tata Memorial Hospital

🇮🇳 Tata Memorial Hospital

Mumbai, India 4.8 (2500 отзывов) 629 коек

Больница занимает 7-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.8 из 5 (2500 отзывов)Аккредитация: NABH629 коек
Специализации и аккредитация
OncologyCancer Center
Аккредитация NABH
4.8/5
Рейтинг
1941
Основана в
629
Койки
Mumbai, India
Расположение
#8
Max Super Specialty Hospital

🇮🇳 Max Super Specialty Hospital

New Delhi, India 4.8 (1300 отзывов) 500 коек

Больница занимает 8-е место в этом списке по указанному рейтингу (4.8/5, 1300 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.8 из 5 (1300 отзывов)Аккредитация: JCI, NABH500 коек
Специализации и аккредитация
CardiacLiver Transplant
Аккредитация JCI, NABH
4.8/5
Рейтинг
2000
Основана в
500
Койки
New Delhi, India
Расположение
#9
Narayana Health

🇮🇳 Narayana Health

Bengaluru, India 4.8 (1750 отзывов) 1,000 коек

Больница занимает 9-е место в этом списке по указанному рейтингу (4.8/5, 1750 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.8 из 5 (1750 отзывов)Аккредитация: NABH1,000 коек
Специализации и аккредитация
CardiacPediatric SurgeryCancer
Аккредитация NABH
4.8/5
Рейтинг
2000
Основана в
1,000
Койки
Bengaluru, India
Расположение
#10
Yashoda Hospitals, Hi-Tech City

🇮🇳 Yashoda Hospitals, Hi-Tech City

Hi-Tech City, Hyderabad, India 4.8 (742 отзывов) 2,000 коек

Больница занимает 10-е место в этом списке по указанному рейтингу (4.8/5, 742 отзывов).

Почему стоит выбрать эту больницу?
Рейтинг 4.8 из 5 (742 отзывов)Аккредитация: JCI, NABH2,000 коек
Специализации и аккредитация
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsOrgan Transplant
Аккредитация JCI, NABH
4.8/5
Рейтинг
1989
Основана в
2,000
Койки
Hi-Tech City, Hyderabad, India
Расположение
Наша методология

Как мы выбираем эти больницы

Больница появляется на этой странице, если направление «Трансплантация печени и гепатобилиарная хирургия» указано среди её специализаций и она находится в Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».

На что обратить внимание

Как выбрать лучшую больницу для «pancreas transplant» в Индия?

Выбор подходящей больницы для «pancreas transplant» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:

Международная аккредитация

Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.

Специализация

Убедитесь, что в больнице есть отделение, специализирующееся на «Трансплантация печени и гепатобилиарная хирургия», а не только общая помощь.

Мощность и опыт

Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.

Прозрачность стоимости

Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.

Клинический обзор

Что нужно знать о процедуре «Pancreas Transplant»

Pancreas transplant surgery is a life-altering procedure that restores endogenous insulin production in patients with insulin-dependent diabetes—most commonly Type 1—and those with chronic pancreatitis leading to total pancreatic endocrine failure. With overall 1-year graft survival rates exceeding 85% at high-volume centers and patient survival rates above 95%, it remains the only currently available cure for insulin-dependent diabetes when performed alongside or after a kidney transplant. GAF Healthcare connects international patients with JCI- and NABH-accredited institutions in India and JCI- and DHA-accredited centers in the UAE, providing end-to-end medical coordination, transparent cost structures, and dedicated case management from first consultation through long-term immunosuppression follow-up. Hospital Stay: 14–21 days • Total Stay in Country (Fit-to-Fly): 6–10 weeks • Success Rate: 85–92% (1-year pancreas graft survival at high-volume centers)

Clinical Overview
Who is a Candidate?
Treatment Options & Approaches
Восстановление

Clinical Overview

The pancreas serves a dual physiological role: its exocrine component produces digestive enzymes essential for nutrient absorption, while its endocrine islet cells—specifically the beta cells of the Islets of Langerhans—secrete insulin and glucagon to maintain glycemic homeostasis. In Type 1 diabetes mellitus, autoimmune destruction of beta cells leads to absolute insulin deficiency, forcing patients into lifelong exogenous insulin dependency with attendant risks of hypoglycemic unawareness, diabetic nephropathy, retinopathy, neuropathy, and cardiovascular disease. In advanced cases of chronic pancreatitis or post-total pancreatectomy states, both exocrine and endocrine function are lost simultaneously. Pancreas transplantation replaces the diseased or absent gland with a vascularized allograft from a deceased donor, restoring physiological insulin secretion in a glucose-responsive, pulsatile manner that no exogenous insulin regimen can replicate. The procedure eliminates hypoglycemic unawareness, halts or reverses secondary diabetic complications in many patients, and dramatically improves quality of life. Three internationally recognized procedural categories exist: Simultaneous Pancreas-Kidney (SPK) transplant—the most common and most successful variant—performed when diabetic nephropathy has caused end-stage renal disease; Pancreas After Kidney (PAK) transplant, for patients who have already received a functioning renal allograft; and Pancreas Transplant Alone (PTA), reserved for patients with brittle diabetes and preserved renal function but life-threatening hypoglycemia. The current standard of care at leading transplant centers integrates donor-recipient histocompatibility matching via HLA typing and Panel Reactive Antibody (PRA) testing, cold ischemia time optimization to under 12 hours, enteric drainage of exocrine secretions (superior to the older bladder-drainage technique), and systemic venous drainage. Immunosuppression protocols typically employ induction therapy with anti-thymocyte globulin (ATG) or basiliximab, followed by maintenance triple therapy comprising a calcineurin inhibitor (tacrolimus), an antiproliferative agent (mycophenolate mofetil), and a tapering corticosteroid course. Rejection surveillance relies on serum amylase and lipase trends, HbA1c normalization, C-peptide levels, and—when indicated—percutaneous or endoscopic graft biopsy graded by Banff schema criteria.

Who is a Candidate?

• IDEAL CANDIDATES: • Type 1 diabetes mellitus with absolute insulin deficiency confirmed by low fasting C-peptide levels (<0.3 ng/mL) • Brittle (labile) diabetes with recurrent, severe hypoglycemia or hypoglycemic unawareness unresponsive to optimal medical management including continuous glucose monitors and closed-loop insulin pump systems • Diabetic nephropathy with eGFR <20 mL/min/1.73m² (SPK) or functioning renal allograft (PAK) • Type 1 diabetes without renal failure but with life-threatening metabolic instability (PTA) • Post-total pancreatectomy patients requiring islet autotransplantation (IAT) or whole-organ allograft • Patients aged 18–55 years (relative; selected centers accept up to 60 years with individualized assessment) • REQUIRED PRE-TRANSPLANT DIAGNOSTICS: • Comprehensive metabolic panel, HbA1c, fasting C-peptide, auto-antibodies (GAD65, IA-2, ZnT8) • ABO blood group and HLA tissue typing; Panel Reactive Antibody (PRA) testing; crossmatch • 2D Echocardiogram (ECHO) and stress testing (dobutamine stress ECHO or nuclear perfusion scan) to exclude occult coronary artery disease • Cardiac catheterization if stress test is positive or equivocal • Renal function panel: 24-hour urine protein, eGFR, renal ultrasound; nuclear GFR if borderline • CT angiography of the abdomen and pelvis to assess iliac vessel anatomy for graft implantation planning • Chest X-ray, pulmonary function tests, and infectious disease serology (CMV, EBV, HIV, Hepatitis B/C, TB QuantiFERON) • Colonoscopy (if age >50 or symptomatic), dental and ophthalmology clearance • Psychosocial evaluation and confirmation of medication adherence capacity • ABSOLUTE CONTRAINDICATIONS: • Active malignancy or remission <2–5 years (tumor-type dependent) • Active systemic infection or untreated sepsis • Severe irreversible cardiac disease (ejection fraction <25%) or unrevascularizable coronary artery disease • Severe peripheral vascular disease precluding safe iliac anastomosis • Active substance abuse or inability to commit to lifelong immunosuppression • Morbid obesity (BMI >35) at most centers (relative contraindication; assessed individually) • Severe pulmonary hypertension or advanced hepatic cirrhosis • Active psychiatric illness that precludes informed consent or post-transplant adherence

Treatment Options & Approaches

SIMULTANEOUS PANCREAS-KIDNEY (SPK) TRANSPLANT — STANDARD APPROACH: The SPK procedure is performed under general anesthesia via a midline or bilateral lower-quadrant laparotomy. The pancreatic allograft (procured with the duodenal segment intact) is implanted in the right iliac fossa with arterial reconstruction using a donor Y-graft (iliac artery bifurcation) anastomosed end-to-side to the recipient right common or external iliac artery. Venous drainage is achieved via end-to-side anastomosis to the right common iliac vein (systemic drainage) or, at select centers using the portal-enteric drainage technique, to the superior mesenteric vein for more physiological insulin delivery directly into the portal circulation. Exocrine secretions are drained via a duodeno-jejunostomy (enteric drainage)—now the preferred technique globally—avoiding the metabolic complications of the older bladder-drainage method. The renal allograft is implanted separately in the left iliac fossa using standard techniques. Total operative time is typically 4–6 hours. PANCREAS AFTER KIDNEY (PAK) AND PANCREAS TRANSPLANT ALONE (PTA): These are technically similar to the SPK pancreas implantation but performed as single-organ procedures. PTA candidates must meet stringent metabolic criteria, and careful risk-benefit analysis is essential given the immunosuppression burden without the concomitant renal benefit. MINIMALLY INVASIVE AND ROBOTIC-ASSISTED APPROACHES: A small number of high-volume academic centers have begun performing robotic-assisted pancreas transplantation using the da Vinci Xi surgical system. This technique involves 4–5 port placements and uses intracorporeal vascular anastomosis. Reported advantages include reduced wound complications (particularly in obese patients), lower incidence of incisional hernia, and shorter hospital stay. While not yet the global standard, robotic pancreas transplantation represents the most advanced frontier of the procedure and is available at select centers partnered with GAF Healthcare. ISOLATED ISLET CELL TRANSPLANTATION (EDMONTON PROTOCOL): For selected PTA candidates—particularly those with prohibitive surgical risk—intraportal infusion of purified islet cells (700,000–1,000,000 islet equivalents) from one or two donors can restore partial or complete insulin independence. The Edmonton Protocol, refined with anti-inflammatory induction (etanercept, exenatide) and steroid-free immunosuppression, achieves insulin independence in approximately 50–60% of patients at 5 years. Islet transplantation is performed as a minimally invasive percutaneous transhepatic procedure under fluoroscopic guidance and does not require general anesthesia or major surgery. However, it requires an approved islet processing facility and is offered at specialized centers. TOTAL PANCREATECTOMY WITH ISLET AUTOTRANSPLANTATION (TP-IAT): For patients with chronic pancreatitis, TP-IAT removes the diseased pancreas, isolates the patient's own islet cells in a sterile processing laboratory, and reinfuses them into the portal vein intraoperatively. Because autologous cells are used, immunosuppression is not required. Insulin independence is achieved in approximately 30–40% of patients; partial function (reducing insulin requirements) is achieved in a further 30–40%. IMMUNOSUPPRESSION PROTOCOLS AND REJECTION MANAGEMENT: Induction: ATG (anti-thymocyte globulin, e.g., Thymoglobulin) or IL-2 receptor antagonist (basiliximab) at the time of transplant. Maintenance: Tacrolimus (target trough 8–12 ng/mL in early months, weaned to 5–8 ng/mL), Mycophenolate Mofetil (1–1.5 g twice daily), and prednisolone (tapering from 20 mg/day to 5 mg/day over 3–6 months; steroid-free protocols considered after 1 year). Acute rejection is treated with pulse methylprednisolone; antibody-mediated rejection (AMR) with plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab (anti-CD20 monoclonal antibody).

Восстановление

PHASE 1 — REMOTE EVALUATION (Weeks 1–3 before travel): Patients submit medical records, recent labs, imaging, and cardiac evaluation results to the GAF Healthcare clinical coordination team. A senior transplant nephrologist and pancreatic transplant surgeon review the case remotely. Virtual consultation is scheduled to confirm candidacy, discuss procedure type (SPK/PAK/PTA), review waitlist logistics (deceased donor) or living-related evaluation, and issue a detailed cost estimate and preliminary treatment plan. PHASE 2 — ARRIVAL AND PRE-TRANSPLANT WORKUP (Days 1–7 in country): Upon arrival, the patient undergoes a structured inpatient or outpatient pre-transplant evaluation: repeat HLA crossmatch with the identified deceased donor (if transplant is imminent), repeat ECHO, CT angiography review, infectious serology confirmation, and anesthesia fitness assessment. Immunosuppression induction medications are initiated. For deceased-donor transplants, patients may be placed on an active waitlist at the center and must remain in-country. Living-donor pancreas transplantation (rare; partial graft from living donor) is evaluated separately. PHASE 3 — SURGERY DAY (Day 0): On receipt of a suitable donor organ (cold ischemia time <12 hours is prioritized), the patient proceeds to the operating theater. General anesthesia is induced. The surgical team performs vascular and enteric anastomoses as described above. Intraoperative graft perfusion is confirmed by Doppler ultrasound on the table. Intraoperative blood glucose normalization—typically within 1–2 hours of pancreatic reperfusion—confirms immediate graft function. Operative duration: 4–6 hours (SPK: 5–8 hours). PHASE 4 — INTENSIVE CARE UNIT (Days 1–3 post-op): Patient is monitored in the ICU or high-dependency unit. Hourly blood glucose monitoring; target range 70–140 mg/dL without exogenous insulin indicates primary graft function. Serum amylase, lipase, creatinine (for SPK), and urine output are tracked. IV tacrolimus or oral tacrolimus is initiated. Doppler ultrasound of graft vessels performed on Day 1 to exclude vascular thrombosis—the most feared early complication. PHASE 5 — WARD RECOVERY (Days 4–14): Progressive ambulation from Day 3 onward. Oral diet re-introduced from Day 3–5 following confirmation of bowel function (enteric drainage). Oral immunosuppression fully established. Twice-daily blood glucose monitoring continues; exogenous insulin is withheld if glucose remains <140 mg/dL. Serum tacrolimus trough levels monitored every 2–3 days and dose adjusted. Rejection surveillance with clinical parameters and labs; graft biopsy if amylase/lipase spikes or unexplained hyperglycemia occurs. PHASE 6 — PRE-DISCHARGE EDUCATION (Days 14–21): Patient and caregiver are comprehensively trained in: daily blood glucose and blood pressure monitoring; immunosuppression schedule and medication storage; signs of rejection (fever, graft tenderness, rising glucose, rising creatinine for SPK); infection prophylaxis protocols (trimethoprim-sulfamethoxazole for PCP, valganciclovir for CMV, fluconazole for fungal prophylaxis). Discharge planning and outpatient follow-up schedule established. PHASE 7 — POST-DISCHARGE OUTPATIENT FOLLOW-UP IN COUNTRY (Weeks 3–6): Weekly outpatient clinic visits for labs: tacrolimus trough, CBC, comprehensive metabolic panel, fasting glucose, HbA1c at Week 6, C-peptide. Any rejection episode or surgical complication is managed during this critical window. Physical activity is gradually increased; driving and heavy lifting are restricted for 6–8 weeks. FIT-TO-FLY MILESTONE (Weeks 6–10): Clearance for international air travel requires: stable graft function (fasting glucose <126 mg/dL without insulin, stable tacrolimus troughs), absence of active infection or rejection, wound fully healed, and surgeon sign-off. GAF Healthcare coordinates a summary medical report and adequate immunosuppression medication supply (minimum 3-month supply) for the return journey. Patients are connected with a transplant center in their home country for ongoing immunosuppression monitoring.

Возможные риски

Pancreas transplantation carries a defined risk profile that patients must understand and weigh against the long-term burden of insulin-dependent diabetes and its complications. Surgical risks include vascular thrombosis of the graft (affecting 5–10% of cases and often requiring urgent re-exploration or graft loss), anastomotic leak at the duodeno-jejunostomy (1–5%), intra-abdominal bleeding, and wound infection—rates are higher than many solid organ transplants due to the contaminated duodenal segment. Graft pancreatitis (from ischemia-reperfusion injury) occurs in approximately 10–20% and usually resolves conservatively. Primary non-function (graft failure from Day 1) occurs in 2–5% and requires immediate return to insulin therapy. Immunological risks include acute cellular rejection (10–20% in the first year), antibody-mediated rejection (more difficult to treat), and chronic allograft failure leading to progressive loss of insulin independence over years. Immunosuppression-related risks are significant and lifelong: tacrolimus nephrotoxicity can paradoxically accelerate renal decline (particularly relevant in PTA patients), new-onset diabetes after transplant (NODAT) from calcineurin inhibitors affects a minority, and the cumulative risk of opportunistic infections (CMV disease, BK virus nephropathy, Pneumocystis jirovecii pneumonia, invasive fungal infections) requires vigilant prophylaxis and monitoring. Long-term immunosuppression also carries a 2–4 fold increased risk of de novo malignancy, particularly non-melanoma skin cancers and post-transplant lymphoproliferative disorder (PTLD). Cardiovascular risk remains elevated in this patient population and requires aggressive lipid management and blood pressure control post-transplant. All patients must be counseled that graft survival is not guaranteed indefinitely—5-year pancreas graft survival in SPK is approximately 73–80%—and that return to insulin therapy may ultimately be required, though usually after years of insulin-free quality life.

Почему GAF Healthcare

GAF Healthcare provides comprehensive non-medical coordination to ensure that international patients can focus entirely on their treatment and recovery. VISA AND ENTRY DOCUMENTATION — INDIA: India's e-Medical Visa (e-MV) is available to citizens of over 160 countries and can be obtained online within 3–5 business days through the Indian government's official portal. The e-MV allows two attendants per patient, each eligible for an e-Medical Attendant Visa (e-MAV). GAF Healthcare's visa assistance team provides complete document checklists, hospital invitation letters on official letterhead, and step-by-step application guidance. Visa extensions within India can be coordinated through the FRRO (Foreigners Regional Registration Office) if the recovery period exceeds the initial visa validity—GAF Healthcare manages this process directly on behalf of the patient. VISA AND ENTRY DOCUMENTATION — UAE: The UAE offers visa-on-arrival or visa-free entry to over 60 nationalities. For other nationalities, a UAE Medical Visa can be arranged through the partnering hospital's international patient services department. GAF Healthcare coordinates with DHA (Dubai Health Authority)-accredited hospitals to facilitate pre-approval letters and visa sponsorship where required. The UAE's geographic position—a maximum 8-hour flight from most of the Middle East, Africa, South Asia, and Eastern Europe—makes it highly accessible for patients who require shorter travel times. AIRPORT TRANSFERS: Private ambulance-equipped or wheelchair-accessible vehicles are arranged for arrival and departure at all partner airports (Indira Gandhi International, Mumbai Chhatrapati Shivaji, Delhi/NCR, Dubai International, Abu Dhabi International). Transfers include a trained medical escort when clinically appropriate for high-acuity patients. DEDICATED CASE MANAGER AND TRANSLATORS: Every GAF Healthcare patient is assigned a dedicated Case Manager who serves as the single point of contact throughout the entire journey—from document preparation through discharge. On-ground translators are available for Arabic, Russian, French, Swahili, Bengali, and other major languages at partnered hospitals. Medical interpretation during surgical consultations, consent procedures, and discharge education is provided at no additional charge through GAF Healthcare's network. ACCOMMODATION FOR ATTENDANTS: Given the 6–10 week in-country stay required for pancreas transplant, GAF Healthcare pre-negotiates discounted rates at serviced apartments and medical-stay hotels adjacent to all partner hospitals. These accommodations are equipped with kitchenettes, laundry, reliable internet, and in some cases shuttle services to the hospital—essential for the one or two attendants who accompany transplant patients. A daily on-call support line staffed by GAF Healthcare coordinators ensures that attendants have 24/7 logistical support throughout the stay.

Частые вопросы о процедуре «Pancreas Transplant»

What is the cost of Pancreas Transplant Surgery in India compared to the UAE?
Pancreas transplant surgery in India at JCI- and NABH-accredited high-volume transplant centers typically costs between USD 18,000 and USD 30,000 for the complete procedure, including the surgery, ICU and ward hospital stay of 14–21 days, standard immunosuppression induction medications, and routine post-operative labs and Doppler monitoring. This is comprehensive of surgical team fees, anesthesia, and standard nursing care. In the UAE—at JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi—the equivalent procedure costs between USD 45,000 and USD 75,000, reflecting the higher infrastructure costs, premium hospital environments, and the UAE's overall healthcare cost structure. Both destinations offer comparable surgical expertise and outcomes at high-volume centers. The cost differential of approximately 40–60% in favor of India makes it the preferred destination for cost-conscious patients, while the UAE is preferred by patients from the Middle East and Africa who prioritize geographic proximity, luxury accommodation standards, and Arabic-language medical care. GAF Healthcare provides fully itemized cost estimates for both destinations prior to any travel commitment, with no hidden charges.
How long do I need to stay in the country before I am fit to fly home after a Pancreas Transplant?
Pancreas transplantation requires one of the longest mandatory in-country stays of any solid organ transplant procedure. Patients should plan for a total stay of 6 to 10 weeks from the date of surgery before being medically cleared for international air travel. The initial hospital stay is typically 14–21 days, covering ICU monitoring, surgical recovery, and initiation of oral immunosuppression. Following discharge, weekly outpatient clinic visits are mandatory for a further 3–6 weeks to monitor tacrolimus trough levels, graft function (fasting glucose, serum amylase/lipase, C-peptide), and to detect and treat any early rejection episode before it results in irreversible graft loss. Fit-to-fly clearance requires documented stable graft function with fasting blood glucose below 126 mg/dL without insulin, fully healed surgical incision, no active infection or rejection, and written surgical clearance. The prolonged post-operative monitoring period is non-negotiable for this procedure and should be factored into all logistical and financial planning. GAF Healthcare coordinates pre-negotiated long-stay accommodation for patients and their attendants throughout this period.
What is the success rate of Pancreas Transplant Surgery?
Success rates for pancreas transplantation are measured in terms of both patient survival and pancreas graft survival, and vary by procedure type. For Simultaneous Pancreas-Kidney (SPK) transplantation—the most common and most successful category—1-year patient survival exceeds 95% at high-volume centers, and 1-year pancreas graft survival (defined as insulin independence) ranges from 85% to 92%. At 5 years, pancreas graft survival in SPK is approximately 73–80%, meaning the majority of patients remain insulin-free at five years post-transplant. Pancreas After Kidney (PAK) transplant has slightly lower 1-year graft survival of approximately 78–85%, and Pancreas Transplant Alone (PTA) ranges from 75–83% at 1 year. Islet cell transplantation (Edmonton Protocol) achieves insulin independence in approximately 50–60% of patients at 5 years, though many retain partial graft function that substantially reduces hypoglycemia risk even without full insulin independence. These outcomes are strongly correlated with transplant center volume—centers performing more than 25–30 pancreas transplants annually show consistently superior results. All GAF Healthcare partner centers for pancreas transplantation are high-volume, internationally accredited institutions with outcomes data available for patient review during the pre-travel consultation process.
Стоимость лечения

Стоимость лечения (Трансплантация печени и гепатобилиарная хирургия) в Индия

Открыть калькулятор стоимости

Только из опубликованных, проверенных руководств по стоимости. Каждая строка открывает полную разбивку.

ДиагнозДиапазон, USD
Трансплантация печени$28,000–$55,000Подробнее →

Это ориентировочные плановые оценки, а не расценка. Итоговая стоимость зависит от вашего случая, выбора больницы и продолжительности пребывания.

Как GAF Healthcare помогает выбрать лучшую больницу для «pancreas transplant» в Индия

Найдите лучшие больницы для «pancreas transplant» в Индия

На этой странице представлено 90 больниц в Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.

Поддержка, когда она нужна

Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.

Прозрачные, всё включено цены

Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.

Организация визы, поездки и проживания

После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.

Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.

Частые вопросы

Частые вопросы о «Pancreas Transplant» в Индия

Сколько больниц направления «Трансплантация печени и гепатобилиарная хирургия» представлено в Индия?
Сейчас в Индия представлено 90 больниц.
Как вы выбираете больницы для списка?
Больница появляется на этой странице, если направление «Трансплантация печени и гепатобилиарная хирургия» указано среди её специализаций и она находится в Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Сколько стоит лечение в Индия?
По нашим опубликованным и проверенным данным, стоимость варьируется от 28,000 до 55,000 долларов США в зависимости от диагноза. См. таблицу "Стоимость лечения" выше.
🤔

Остались вопросы?

Наша команда готова ответить на вопросы о «Pancreas Transplant» в Индия.

Следующий шаг

Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Pancreas Transplant» в Индия.

Свяжитесь с нами, если заметите неточность на этой странице.